Chester County News and Community Website
PHOENIXVILLE, PA — PleoPharma has dosed the first patient in a Phase 3 clinical trial of an investigational treatment for cannabis withdrawal symptoms, advancing a drug candidate that could become …
PleoPharma Begins Phase 3 Trial for Cannabis Withdrawal Drug Read More
WEST CHESTER, PA — Molecular Targeting Technologies Inc. reported updated clinical data from 81 patients with gastroenteropancreatic neuroendocrine tumors treated with its experimental radiopharmaceutical EBTATE, results that the company says …
MTTI Reports Extended Disease Control Data in Neuroendocrine Tumor Study Read More
WAYNE, PA — Teleflex Incorporated (NYSE: TFX) reported four-year follow-up results from a first-in-human clinical study of its Freesolve resorbable magnesium coronary scaffold, providing long-term safety data as the company …
Teleflex Reports Four-Year Data for Resorbable Heart Scaffold Read More
WAYNE, PA — Palvella Therapeutics Inc. (Nasdaq: PVLA) said it remains on track to submit a New Drug Application in the second half of 2026 for its lead therapy targeting …
Palvella Advances Rare Disease Drug Toward FDA Filing Read More WAYNE, PA — Teleflex (NYSE: TFX) reported new clinical data supporting two of its urology products as the company prepares to divest its Interventional Urology business later this year, a …
Teleflex Reports New Data Ahead of Urology Unit Sale Read More
WASHINGTON, D.C. — The Department of Veterans Affairs is launching a clinical trial of MDMA-assisted therapy for veterans with post-traumatic stress disorder and alcohol use disorder, expanding federal research into …
VA Launches MDMA Trial for PTSD, Alcohol Use Disorders Read More WAYNE, PA — Palvella Therapeutics (Nasdaq: PVLA) reported new late-stage clinical data showing strong patient response rates for its experimental QTORIN rapamycin treatment in rare vascular malformations, positioning the company …
Palvella Reports Late-Stage Success for Rare Disease Drug Read More
MALVERN, PA — Annovis Bio, Inc. (NYSE: ANVS) reported that enrollment in its pivotal Phase 3 Alzheimer’s disease trial has reached 85% and remains on track for completion this summer, …
Annovis Nears Full AD Enrollment Ahead of NDA Plans Read More WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) presented new Phase 2 data showing statistically significant reductions in lesion bleeding among patients treated with QTORIN rapamycin for cutaneous venous malformations, …
Palvella Advances Rare Disease Program With Phase 2 Data Read More WAYNE, PA — Palvella Therapeutics (Nasdaq: PVLA) recently dosed the first patients in a Phase 2 study evaluating QTORIN rapamycin gel for angiokeratomas, a rare vascular-related skin disorder with no …
Palvella Doses First Patients in Rare Disease Skin Trial Read More